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In the great majority of human tumors,
the p53 pathway is disarmed by onco-
genic mutations in p53 itself, expression
of viral oncoproteins, or defective p53
upstream regulation (Vogelstein et al.,
2000). The growing understanding of its
physiological function has revealed that
p53 is a key regulator of apoptosis, in
addition to its clear effects on cell cycle
arrest and its involvement in senes-
cence, DNA repair, differentiation, and
other processes. It was a serendipitous
finding that expression of wild-type p53
resulted in rapid loss of cell viability with
characteristics of apoptosis (Yonish-
Rouach et al., 1991). Indisputable evi-
dence for the role of p53 in physiological
cell death was later provided by studies
of p53 knockout mice (Lowe et al., 1993;
Clarke et al., 1993). Thymocytes and
stem cells of the intestine
derived from these animals are
significantly more resistant to
radiation-induced apoptosis
than corresponding normal
cells. Cellular stresses that
induce p53-dependent apopto-
sis include DNA damage, onco-
gene activation, hypoxia, and
oxidative stress. Under these
conditions, p53 is essential for
restricting inappropriate cell pro-
liferation and thereby suppress-
es neoplasia.
With the role of p53 in apop-
tosis established, the burning
question became how p53 initi-
ated apoptosis in response to
these stresses. p53 is a tran-
scription factor that directly
binds to DNA in a sequence-
specific manner to activate its
downstream targets (Kern et al.
1991). There are hundreds of
sites in the human genome that
can be bound by p53. A number
of large-scale gene expression
analyses have been performed
to look for the p53 targets. p21
and 14-3-3σ were thus identified
and confirmed by gene-target-
ing experiments to be the major media-
tors of p53-induced cell cycle arrest
(Vogelstein et al., 2000). In contrast, the
search for a major apoptotic mediator of
p53 has been long and difficult. At least
16 genes have been reported to play a
role in p53-dependent apoptosis
(Vousden and Lu, 2002). These genes
are directly involved in regulation of
apoptosis and can be activated by p53 in
response to stresses. In each case, a
consensus p53 binding site was located
within the regulatory region of the gene.
However, deletion of these genes in mice
never recapitulated the apoptotic pheno-
type of the p53 knockout mice, and the
importance of these genes for p53-
dependent apoptosis has remained con-
jectural.
A latecomer to the group of p53 tar-
gets is a protein called PUMA, or p53
upregulated modulator of apoptosis.
PUMA was initially identified as a gene
activated by p53 in cells undergoing p53-
induced apoptosis (Yu et al., 2001;
Nakano and Vousden, 2001), and as a
protein interacting with Bcl-2 (Han et al.,
2001). PUMA and another p53 target
Noxa share homology with Bcl-2 family
proteins, but only within a short stretch of
amino acids termed the BH3 (Bcl-2
homology 3) domain. Proteins with simi-
lar homology, coined as “BH3-only” pro-
teins, have been suggested to play an
essential role in apoptosis initiation
(Bouillet and Strasser, 2002). Several
hurdles had prevented PUMA from being
identified in earlier attempts, including its
low expression level, GC-rich coding
sequence, lack of sequence homology to
known apoptotic proteins, and
diversity of transcripts due to
alternative splicing. Several
characteristics distinguish
PUMA from other p53 targets.
For example, the coding and
regulatory sequences of PUMA,
including those that are directly
bound by p53, are highly con-
served among different species.
PUMA is also extremely effec-
tive in inducing apoptosis: when
expressed, it kills cancer cells
within a few hours. And impor-
tantly, gene knockouts in human
colorectal cancer cells showed
that PUMA was required for
apoptosis induced by p53,
hypoxia, and DNA-damaging
agents (Yu et al., 2003).
Nevertheless, evidence validat-
ing the role of PUMA in physio-
logical cell death in an intact
animal was lacking.
This evidence is now provid-
ed by two studies describing
striking phenotypes of PUMA
knockout mice. One, led by
Gerard Zambetti at the St. Jude
Children’s Research Hospital, is
published in this issue of Cancer
Figure 1. PUMA is essential for p53-dependent and -indepen-
dent apoptosis
p53 induces either cell cycle arrest or apoptosis depending on
cell type and subcellular context. PUMA is required for p53-
dependent apoptosis induced by DNA damage, hypoxia, and
oncogenes. PUMA is also necessary for apoptosis induced by
p53-independent stimuli including serum withdrawal, glucocor-
ticoids, kinase inhibitors, and phorbol esters. p53-dependent
cell cycle arrest is mediated by p21 and 14-3-3σ.
No PUMA, no death: Implications for p53-dependent apoptosis
More than a decade ago, it was found that one of the two essential physiological functions of p53 is to selectively destroy
stressed cells through apoptosis. Despite the large number of studies describing p53-dependent apoptosis since then,
how p53 turns on the apoptotic switch has remained enigmatic. In this issue of Cancer Cell, Jeffers et al. report that knock-
out of PUMA, a recently identified BH3-only Bcl-2 family protein, recapitulates virtually all apoptotic deficiency in p53
knockout mice.Their results indicate that PUMA is an essential mediator of p53-dependent and -independent apoptosis in
vivo.
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Cell (Jeffers et al., 2003). The other, led
by Andreas Strasser at the Walter and
Eliza Hall Institute of Medical Research
in Melbourne, Australia, is described in
Science (Villunger et al., 2003). Both
studies show that knockout of PUMA can
recapitulate the majority, if not all, of the
apoptotic deficiencies observed in p53
knockout mice. Thymocyte apoptosis
induced by γ-irradiation and DNA-dam-
aging drugs, considered by many as the
“gold standard” for analyzing p53-medi-
ated physiological cell death, was
blocked in the PUMA knockout mice to a
similar extent as in p53 knockout mice.
PUMA is required for the p53-dependent
apoptotic responses to the c-Myc and
E1A oncogenes in primary embryonic
fibroblast (MEF) cells, and also is neces-
sary for the DNA damage-induced apop-
tosis that occurs in developing neurons.
Furthermore, PUMA deficiency protects
lymphocytes from p53-independent apo-
ptotic stimuli such as cytokine withdrawal
or exposure to the glucocorticoid dexam-
ethasone, the kinase inhibitor stau-
rosporine, or phorbol esters. The
Strasser group also characterized Noxa
knockout mice and found some effects
on the apoptotic phenotype, though not
as pronounced as those found with
PUMA. Both PUMA and Noxa are dis-
pensable for normal development, as is
p53.
Although these studies unequivocal-
ly demonstrate the essential role of
PUMA in p53-dependent apoptosis, sev-
eral critical questions remain. First, do
spontaneous tumors develop in the
PUMA knockout mice? The complete
loss of p53 results in the development of
tumors, predominantly lymphomas and
sarcomas (Donehower et al., 1992).
Neither paper has reported any tumors
in the PUMA knockout mice, at least at
their current age (6 months, a time when
tumors in p53 knockout mice are already
evident). These data suggest that inacti-
vation of the apoptotic function of p53
alone may not be sufficient for tumorige-
nesis and that abrogation of both the cell
cycle and apoptotic effects of p53 is
required for efficient tumorigenesis. The
cross between PUMA-deficient mice and
p21-deficient mice is therefore eagerly
awaited. Second, does p53 directly acti-
vate PUMA transcription to initiate apop-
tosis in vivo, which is the case in human
cancer cells (Yu et al., 2001), or induce
apoptosis via transcription-independent
mechanisms (Vousden and Lu, 2002)?
To address this issue in the intact mouse,
the p53 binding sites and other regulato-
ry elements within the PUMA promoter
could be manipulated using gene-target-
ing approaches. Third, is PUMA related
to other apoptotic mediators of p53? It is
possible that some proteins influence
p53-dependent apoptosis by regulating
PUMA or by being regulated by PUMA.
For instance, PUMA functions through
Bax to induce apoptosis in human col-
orectal cancer cells, even though Bax is
not directly regulated by p53 in many
cells (Yu et al., 2003). Another interesting
question is whether PUMA deficiency
can mimic p53 deficiency in its ability to
rescue the developmental defects
caused by MDM2 knockout. And finally,
why do some cells undergo cell cycle
arrest rather than apoptosis in response
to p53, even though PUMA is induced?
Studies of PUMA knockout mice
have several important implications for
cancer biology and therapy. Although
there is no evidence that PUMA is either
mutated or abnormally expressed in
tumors with normal p53, the knockout
studies will undoubtedly stimulate further
analysis of such tumors. More important-
ly, PUMA can potentially be used as a
new target for anticancer therapy. Loss of
apoptotic response by inactivating the
p53 pathway appears to be required for
malignant progression. Agents that acti-
vate PUMA via p53-independent mecha-
nisms might restore the apoptotic
response in tumor cells while sparing
normal cells. It will be of interest to deter-
mine whether PUMA can sensitize p53
mutant cells to anticancer drugs.
Although many questions await
answers, the identification of PUMA as
an essential mediator of apoptosis is a
significant step in understanding the
physiological functions of p53. Hopefully,
it will not take another decade to develop
an effective therapy based on these dis-
coveries.
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